Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement.

Wang, Ting; McAuslane, Neil; Goettsch, Wim G; Leufkens, Hubert G M; De Bruin, Marie L

Wang, Ting; McAuslane, Neil; Goettsch, Wim G; Leufkens, Hubert G M; De Bruin, Marie L.

Afiliação

Wang T; Centre for Innovation in Regulatory Science (CIRS), London, UK.
McAuslane N; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Goettsch WG; Centre for Innovation in Regulatory Science (CIRS), London, UK.
Leufkens HGM; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
De Bruin ML; National Health Care Institute, Diemen, The Netherlands.

Int J Technol Assess Health Care ; 39(1): e20, 2023 Apr 11.

Article em En | MEDLINE | ID: mdl-37039100

Assuntos

Ecossistema; Avaliação da Tecnologia Biomédica; Humanos; Política de Saúde; Desenvolvimento de Medicamentos; Inquéritos e Questionários

Palavras-chave

Collaboration; Early scientific advice; Evidentiary requirement; Health technology assessment; Stakeholder interactions

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Avaliação da Tecnologia Biomédica / Ecossistema Tipo de estudo: Guideline / Health_technology_assessment / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google